Cargando…

Relation of plasma PCSK9 levels to lipoprotein subfractions in patients with stable coronary artery disease

BACKGROUND: Plasma PCSK9 levels was positively associated with low-density lipoprotein (LDL) cholesterol (LDL-C) and atherosclerosis, while PCSK9 may also be implicated in the metabolism of lipoprotein subfractions. The study was to examine the association of plasma PCSK9 with lipoprotein subfractio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xu, Rui-Xia, Li, Sha, Zhang, Yan, Li, Xiao-Lin, Guo, Yuan-Lin, Zhu, Cheng-Gang, Li, Jian-Jun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4292809/ https://www.ncbi.nlm.nih.gov/pubmed/25496400 http://dx.doi.org/10.1186/1476-511X-13-188

Ejemplares similares

Systemic Inflammatory Markers Are Closely Associated with Atherogenic Lipoprotein Subfractions in Patients Undergoing Coronary Angiography
por: Zhang, Yan, et al.
Publicado: (2015)

Effect of PCSK9 inhibition with evolocumab on lipoprotein subfractions in familial dysbetalipoproteinemia (type III hyperlipidemia)
por: Waldmann, Elisa, et al.
Publicado: (2022)

Distribution of High-Density Lipoprotein Subfractions and Hypertensive Status: A Cross-Sectional Study
por: Zhang, Yan, et al.
Publicado: (2015)

Large HDL Subfraction But Not HDL-C Is Closely Linked With Risk Factors, Coronary Severity and Outcomes in a Cohort of Nontreated Patients With Stable Coronary Artery Disease: A Prospective Observational Study
por: Li, Jian-Jun, et al.
Publicado: (2016)

CVD Risk Stratification in the PCSK9 Era: Is There a Role for LDL Subfractions?
por: Kjellmo, Christian Abendstein, et al.
Publicado: (2018)

A Mendelian randomization study of the role of lipoprotein subfractions in coronary artery disease
por: Zhao, Qingyuan, et al.
Publicado: (2021)

Association of PCSK9 plasma levels with metabolic patterns and coronary atherosclerosis in patients with stable angina
por: Caselli, Chiara, et al.
Publicado: (2019)

Acute Coronary Syndrome Remodels the Protein Cargo and Functions of High-Density Lipoprotein Subfractions
por: Tan, Ying, et al.
Publicado: (2014)

Association between Lipoprotein Subfractions, Hemostatic Potentials, and Coronary Atherosclerosis
por: Poropat Flerin, Tadeja, et al.
Publicado: (2022)

Can metformin stabilize PCSK9 level in stable coronary artery disease patients treated with statins?
por: Shek, Aleksandr B., et al.
Publicado: (2019)

Effect of PCSK9 inhibitor on lipoprotein particles in patients with acute coronary syndromes
por: Li, Tingting, et al.
Publicado: (2021)

Association of lipoprotein subfractions and glycoprotein acetylation with coronary plaque burden in SLE
por: Purmalek, Monica M, et al.
Publicado: (2019)

The value of HDL subfractions in predicting cardiovascular outcomes in untreated, diabetic patients with stable coronary artery disease: An age- and gender-matched case-control study
por: Zhang, Wei, et al.
Publicado: (2023)

Decreased APOE-containing HDL subfractions and cholesterol efflux capacity of serum in mice lacking Pcsk9
por: Choi, Seungbum, et al.
Publicado: (2013)

Association of circulating PCSK9 concentration with cardiovascular metabolic markers and outcomes in stable coronary artery disease patients with or without diabetes: a prospective, observational cohort study
por: Peng, Jia, et al.
Publicado: (2020)

Corrigendum: The value of HDL subfractions in predicting cardiovascular outcomes in untreated, diabetic patients with stable coronary artery disease: an age- and gender-matched case-control study
por: Zhang, Wei, et al.
Publicado: (2023)

Correlation between serum levels of proprotein convertase subtilisin/kexin type 9 (PCSK9) and atherogenic lipoproteins in patients with coronary artery disease
por: Nozue, Tsuyoshi, et al.
Publicado: (2016)

Prioritizing the Role of Major Lipoproteins and Subfractions as Risk Factors for Peripheral Artery Disease
por: Levin, Michael G., et al.
Publicado: (2021)

Impact of currently prescribed lipid-lowering drugs on plasma PCSK9 concentration: single or in combination study in rats
por: Zhang, Yan, et al.
Publicado: (2014)

PCSK9 and triglyceride-rich lipoprotein metabolism
por: Druce, Irena, et al.
Publicado: (2015)

Low Density Lipoprotein Binds to Proprotein Convertase Subtilisin/Kexin Type-9 (PCSK9) in Human Plasma and Inhibits PCSK9-mediated Low Density Lipoprotein Receptor Degradation
por: Kosenko, Tanja, et al.
Publicado: (2013)

Lipoprotein subfraction patterns throughout gestation in The Gambia: changes in subfraction composition and their relationships with infant birth weights
por: Woo, Jessica G., et al.
Publicado: (2023)

Effect of Evolocumab on Lipoprotein(a) and PCSK9 in Healthy Individuals with Elevated Lipoprotein(a) Level
por: Afanasieva, Olga, et al.
Publicado: (2020)

Plasma lipoprotein subfraction concentrations are associated with lipid metabolism and age-related macular degeneration
por: Cheung, Chui Ming Gemmy, et al.
Publicado: (2017)

Nonalcoholic steatohepatitis is associated with an atherogenic lipoprotein subfraction profile
por: Corey, Kathleen E, et al.
Publicado: (2014)

Potential Impact on Lipoprotein Subfractions in Type 2 Diabetes
por: Kamijo, Yuka, et al.
Publicado: (2019)

Lipoprotein Subfractions and Glucose Homeostasis in Prediabetes and Diabetes in Taiwan
por: Hsu, Hung, et al.
Publicado: (2019)

Leptin decreases the expression of low-density lipoprotein receptor via PCSK9 pathway: linking dyslipidemia with obesity
por: Du, Ying, et al.
Publicado: (2016)

Positive correlation between plasma PCSK9 and tissue factors levels in patients with angiographically diagnosed coronary artery disease and diabetes mellitus
por: Wang, Mei, et al.
Publicado: (2016)

The elevation of plasma concentrations of apoB-48-containing lipoproteins in familial hypercholesterolemia is independent of PCSK9 levels
por: Drouin-Chartier, Jean-Philippe, et al.
Publicado: (2017)

The Impact of Lipoprotein Apheresis on Oxidative Stress Biomarkers and High-Density Lipoprotein Subfractions
por: Mickiewicz, Agnieszka, et al.
Publicado: (2020)

The predictive utility of circulating PCSK9 levels on diabetes mellitus
por: Peng, Jia, et al.
Publicado: (2021)

PCSK9 Inhibition: Does Lipoprotein Size Matter?
por: Si‐Tayeb, Karim, et al.
Publicado: (2015)

Lipoprotein(a) and PCSK9 inhibition: clinical evidence
por: Ruscica, Massimiliano, et al.
Publicado: (2020)

Impacts of ezetimibe on PCSK9 in rats: study on the expression in different organs and the potential mechanisms
por: Xu, Rui-Xia, et al.
Publicado: (2015)

Serum obestatin level strongly correlates with lipoprotein subfractions in non-diabetic obese patients
por: Szentpéteri, Anita, et al.
Publicado: (2018)

Plasminogen Activator Inhibitor-1 Level Correlates with Lipoprotein Subfractions in Obese Nondiabetic Subjects
por: Somodi, Sándor, et al.
Publicado: (2018)

Intercorrelations of lipoprotein subfractions and their covariation with lifestyle factors in healthy men
por: Parlesak, Alexandr, et al.
Publicado: (2014)

PCSK9 Inhibitors Reduce PCSK9 and Early Atherogenic Biomarkers in Stimulated Human Coronary Artery Endothelial Cells
por: Zulkapli, Rahayu, et al.
Publicado: (2023)

HDL subfractions and very early CAD: novel findings from untreated patients in a Chinese cohort
por: Zhang, Yan, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_nr6itqcqmjqo4k2imgu5rov1t4